SEARCH

SEARCH BY CITATION

References

  • Agius L (2009). Targeting hepatic glucokinase in type 2 diabetes: weighing the benefits and risks. Diabetes 58: 1820.
  • Arendt BM, Mohammed SS, Aghdassi E, Prayitno NR, Ma DW, Nguyen A et al. (2009). Hepatic fatty acid composition differs between chronic hepatitis C patients with and without steatosis. J Nutr 139: 691695.
  • Bebernitz GR, Beaulieu V, Dale BA, Deacon R, Duttaroy A, Gao J et al. (2009). Investigation of functionally liver selective glucokinase activators for the treatment of type 2 diabetes. J Med Chem 52: 61426152.
  • Beer NL, Tribble ND, McCulloch LJ, Roos C, Johnson PR, Orho-Melander M et al. (2009). The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase in liver. Hum Mol Genet 18: 40814088.
  • Bertand M, Jackson P, Walther B (2000). Rapid assessment of drug metabolism in the drug discovery process. Eur J Pharm Sci 11 (Suppl. 2): S61S72.
  • Bertram LS, Black D, Briner PH, Chatfield R, Cooke A, Fyfe MC et al. (2008). SAR, pharmacokinetics, safety, and efficacy of glucokinase activating 2-(4-sulfonylphenyl)-N-thiazol-2-ylacetamides: discovery of PSN-GK1. J Med Chem 51: 43404345.
  • Bi M, Kao WH, Boerwinkle E, Hoogeveen RC, Rasmussen-Torvik LJ, Astor BC et al. (2010). Association of rs780094 in GCKR with metabolic traits and incident diabetes and cardiovascular disease: the ARIC study. Plos ONE 5: e11690.
  • Brocklehurst KJ, Payne VA, Davies RA, Carroll D, Vertigan HL, Wightman HJ et al. (2004). Stimulation of hepatocyte glucose metabolism by novel small molecule glucokinase activators. Diabetes 53: 535541.
  • Cohen JC, Horton JD, Hobbs HH (2011). Human fatty liver disease: old questions and new insights. Science 332: 15191523.
  • Coope GJ, Atkinson AM, Allott C, McKerrecher D, Johnstone C, Pike KG et al. (2006). Predictive blood glucose lowering efficacy by glucokinase activators in high fat fed female Zucker rats. Br J Pharmacol 149: 328335.
  • Eiki J, Nagata Y, Futamura M, Sasaki-Yamamoto K, Iino T, Nishimura T et al. (2011). Pharmacokinetic and pharmacodynamic properties of the glucokinase activator MK-0941 in rodent models of type 2 diabetes and healthy dogs. Mol Pharmacol 80: 11561165.
  • Ferre T, Riu E, Franckhauser S, Agudo J, Bosch F (2003). Long-term overexpression of glucokinase in the liver of transgenic mice leads to insulin resistance. Diabetologia 46: 16621668.
  • Folch J, Lees M, Sloane Stanley GH (1957). A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 226: 497509.
  • Froguel P, Vaxillaire M, Sun F, Velho G, Zouali H, Butel MO et al. (1992). Close linkage of glucokinase locus on chromosome 7p to early-onset non-insulin-dependent diabetes mellitus. Nature 356: 162164.
  • Futamura M, Yao J, Li X, Bergeron R, Tran JL, Zycband E et al. (2012). Chronic treatment with a glucokinase activator delays the onset of hyperglycaemia and preserves beta cell mass in the Zucker diabetic fatty rat. Diabetologia 55: 10711080.
  • Glaser B, Kesavan P, Heyman M, Davis E, Cuesta A, Buchs A et al. (1998). Familial hyperinsulinism caused by an activating glucokinase mutation. N Engl J Med 338: 226230.
  • Gloyn AL, Noordam K, Willemsen MA, Ellard S, Lam WW, Campbell IW et al. (2003). Insights into the biochemical and genetic basis of glucokinase activation from naturally occurring hypoglycemia mutations. Diabetes 52: 24332440.
  • Grimsby J, Sarabu R, Corbett WL, Haynes NE, Bizzarro FT, Coffey JW et al. (2003). Allosteric activators of glucokinase: potential role in diabetes therapy. Science 301: 370373.
  • Kamata K, Mitsuya M, Nishimura T, Eiki J, Nagata Y (2004). Structural basis for allosteric regulation of the monomeric allosteric enzyme human glucokinase. Structure 12: 429438.
  • Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG (2010). NC3Rs Reporting Guidelines Working Group. Br J Pharmacol 160: 15771579.
  • Kotronen A, Seppanen-Laasko T, Westerbacka J, Kiviluoto T, Arola J, Ruskeepaa AL et al. (2009). Hepatic steraoyl-CoA desaturase (SCD)-1 activity and diacylglycerol but not ceramide concentrations are increased in the nonalcoholic human fatty liver. Diabetes 58: 203208.
  • McKerrecher D, Allen JV, Caulkett PW, Donald CS, Fenwick ML, Grange E et al. (2006). Design of a potent, soluble glucokinase activator with excellent in vivo efficacy. Bioorg Med Chem Lett 16: 27052709.
  • Mahalingam B, Cuesta-Munoz A, Davis EA, Matschinsky FM, Harrison RW, Weber IT (1999). Structural model of human glucokinase in complex with glucose and ATP: implications for the mutants that cause hypo- and hyperglycemia. Diabetes 48: 16981705.
  • Matschinsky FM (2009). Assessing the potential of glucokinase activators in diabetes therapy. Nat Rev Drug Discov 8: 399416.
  • Matschinsky FM, Zelent B, Doliba NM, Kaestner KH, Vanderkooi JM, Grimsby J et al. (2011). Research and development of glucokinase activators for diabetes therapy: theoretical and practical aspects. Handb Exp Pharmacol 203: 357401.
  • McGrath J, Drummond G, Kilkenny C, Wainwright C (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 15731576.
  • Meininger GE, Scott R, Alba M, Shentu Y, Luo E, Amin H et al. (2011). Effects of MK-0941, a novel glucokinase activator, on glycemic control in insulin-treated patients with type 2 diabetes. Diabetes Care 34: 25602566.
  • Merglen A, Theander S, Rubi B, Chaffard G, Wollheim CB, Maechler P (2004). Glucose sensitivity and metabolism-secretion coupling studied during two-year continuous culture in INS-1E insulinoma cells. Endocrinology 145: 667678.
  • Miller MH, Ferguson MAJ, Dillon JF (2011). Systematic review of performance of non-invasive biomarkers in the evaluation of non-alcoholic fatty liver disease. Liver Int 31: 461473.
  • Min HK, Kapoor A, Fuchs M, Mirshahi F, Zhou H, Maher J et al. (2012). Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease. Cell Metab 15: 665674.
  • Njølstad PR, Søvik O, Cuesta-Muñoz A, Bjørkhaug L, Massa O, Barbetti F et al. (2001). Neonatal diabetes mellitus due to complete glucokinase deficiency. N Engl J Med 344: 15881592.
  • Nolan CJ, Damm P, Prentki M (2011). Type 2 diabetes across generations: from pathophysiology to prevention and management. Lancet 378: 169181.
  • O'Doherty RM, Lehman DL, Télémaque-Potts S, Newgard CB (1999). Metabolic impact of glucokinase overexpression in liver: lowering of blood glucose in fed rats is accompanied by hyperlipidemia. Diabetes 48: 20222027.
  • Orho-Melander M, Melander O, Guiducci C, Perez-Martinez P, Corella D, Roos C et al. (2008). Common missense variant in the glucokinase regulatory protein gene is associated with increased plasma triglyceride and C-reactive protein but lower fasting glucose concentrations. Diabetes 57: 31123121.
  • Osbak KK, Colclough K, Saint-Martin C, Beer NL, Bellanné-Chantelot C, Ellard S et al. (2009). Update on mutations in glucokinase (GCK), which cause maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemic hypoglycemia. Hum Mutat 30: 15121526.
  • Patel KD, Abeysekera KW, Marlais M, McPhail MJ, Thomas HC, Fitzpatrick JA et al. (2011). Recent advances in imaging hepatic fibrosis and steatosis. Expert Rev Gastroenterol Hepatol 5: 91104.
  • Peter A, Stefan N, Cegan A, Walenta M, Wagner S, Königsrainer A et al. (2011). Hepatic glucokinase expression is associated with lipogenesis and fatty liver in humans. J Clin Endocrinol Metab 96: E1126E1130.
  • Petit P, Antoine M, Ferry G, Boutin JA, Lagarde A, Gluais L et al. (2011). The active conformation of human glucokinase is not altered by allosteric activators. Acta Cryst D 67: 929935.
  • Pino MF, Kim KA, Shelton KD, Lindner J, Odili S, Li C et al. (2007). Glucokinase thermolability and hepatic regulatory protein binding are essential factors for predicting the blood glucose phenotype of missense mutations. J Biol Chem 282: 1390613916.
  • Postic C, Girard J (2008). Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J Clin Invest 118: 829838.
  • Postic C, Shiota M, Magnuson MA (2001). Cell-specific roles of glucokinase in glucose homeostasis. Recent Prog Horm Res 56: 195217.
  • Richard J, Lingvay I (2011). Hepatic steatosis and type 2 diabetes: current and future treatment considerations. Expert Rev Cardiovasc Ther 9: 321328.
  • Roden M (2006). Mechanisms of disease: hepatic steatosis in type 2 diabetes-pathogenesis and clinical relevance. Nat Clin Pract Endocrinol Metab 2: 335348.
  • Samuel VT, Petersen KF, Shulman GI (2010). Lipid-induced insulin resistance: unravelling the mechanism. Lancet 375: 22672277.
  • Santoro N, Zhang CK, Zhao H, Pakstis AJ, Kim G, Kursawe R et al. (2012). Variant in the glucokinase regulatory protein (GCKR) gene is associated with fatty liver in obese children and adolescents. Hepatology 55: 781789.
  • Sarabu R, Berthel SJ, Kester RF, Tilley JW (2011). Novel glucokinase activators: a patent review (2008–2010). Expert Opin Ther Pat 21: 1333.
  • Saxena R, Voight BF, Lyssenko V, Burtt NP, de Bakker PI, Chen H et al. (2007). Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 316: 13311336.
  • Seglen PO (1976). Preparation of isolated rat liver cells. In: Prescott DM (ed.). Methods in Cell Biology, Vol. XIII. Ch. 4. Academic Press: New York, pp. 2983.
  • Smith BW, Adams LA (2011). Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment. Nat Rev Endocrinol 7: 456465.
  • Stefan N, Kantartzis K, Häring HU (2008). Causes and metabolic consequences of fatty liver. Endocr Rev 29: 939960.
  • Szczepaniak LS, Nurenberg P, Leonard D, Browning JD, Reingold JS, Grundy S et al. (2005). Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab 288: E462E468.
  • Toledo FGS, Sniderman AD, Kelley DE (2006). Influence of hepatic steatosis (fatty liver) on severity and composition of dyslipidemia in type 2 diabetes. Diabetes Care 29: 18451850.
  • Ursø B, Cope DL, Kalloo-Hosein HE, Hayward AC, Whitehead JP, O'Rahilly S et al. (1999). Differences in signaling properties of the cytoplasmic domains of the insulin receptor and insulin-like growth factor Receptor in 3T3-L1 adipocytes. J Biol Chem 274: 3086430873.
  • Wabitsch M, Lahr G, Van de Bunt M, Marchant C, Lindner M, von Puttkamer J et al. (2007). Heterogeneity in disease severity in a family with a novel G68V GCK activating mutation causing persistent hyperinsulinaemic hypoglycemia of infancy. Diabet Med 24: 13931399.
  • Willer CJ, Sanna S, Jackson AU, Scuteri A, Bonnycastle LL, Clarke R et al. (2008). Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat Genet 40: 161169.
  • Winzell MS, Coghlan M, Leighton B, Frangioudakis G, Smith DM, Storlien LH et al. (2011). Chronic glucokinase activation reduces glycemia and improves glucose tolerance in high-fat diet fed mice. Eur J Pharmacol 663: 8086.
  • Yee S (1997). In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in man – fact or myth. Pharm Res 14: 763766.